立他司特各版本价格一览

Introduction: Xiidra is the world's first drug for the treatment of dry eye disease that targets lymphocyte function-associated antigen-1 (LFA-1). Its price information, drug preparation management and medication regimen for special groups have important reference value for patient treatment. This article will introduce in detail the market version of this drug, suggestions for reasonable drug preparation, and medication guidance for special groups.

Prices of various versions of Ritalast

Currently, there are relatively few versions in the global market. Understanding the price information will help patients make a better budget for treatment.

Original drug pricing

The specification of Ritalast produced by Shire Pharmaceuticals in the United States is 0.2ml*60 tubes/box. The price currently known is about US$547. The price may fluctuate slightly due to different purchasing channels.

Current status of generic drugs

As of now, no generic drug of Ritalast has been approved for marketing globally, and patients can only choose the original version of the drug for treatment.

Factors affecting price

Patent protection status, R&D costs and market demand jointly determine the current pricing, and some insurance plans may provide cost support.

When purchasing drugs, you should confirm the latest price through formal channels and obtain the complete drug purchase receipt and drug instructions.

The quantity of Ritalast preparations

Reasonable planning of the quantity of preparations is very important to ensure the continuity of treatment and drug quality. The preparation plan needs to comprehensively consider a variety of factors.

Standard preparation dosage

Based on the standard dosage of 2 pills per day, 1 box of medicine is required per month. It is recommended to control the amount of medicine to be used for 1-2 months to avoid large-scale hoarding.

Preparing medicines for special circumstances

During the epidemic or for travel needs, the dosage can be appropriately increased to 3 months upon evaluation by a physician. It is necessary to ensure that the storage conditions of the medicines meet the requirements.

Drug storage requirements

Unopened drugs need to be stored in a dry place at 15-25°C and away from light. Single containers after opening should be used immediately and must not be reused.

Regularly check drug inventory and expiration dates to ensure that drugs are used reasonably within the expiration date.

Ritalast medication for special groups

Patients with different physiological states need to pay special attention to the adjustment of the medication regimen when using Ritalast. The following guidance and suggestions are for reference.

Pregnant women

There is no data on use by pregnant women. Animal experiments show that high doses may be teratogenic. It should be used with caution after strict evaluation of the benefit-risk ratio during pregnancy.

Lactating women

There is no data on the concentration of the drug in breast milk. If you need to use it during breastfeeding, it is recommended to suspend breastfeeding or choose an alternative treatment plan.

Pediatric patients

The safety and effectiveness of patients under 17 years of age have not been established, and the decision whether to use it needs to be evaluated by an ophthalmologist.

Elderly patients

Compared with young patients, there is no significant difference in safety and effectiveness, but it should be noted that elderly patients may have other eye diseases.

Special groups need to develop individualized plans for medication by specialists, strengthen monitoring during treatment, and adjust medication strategies in a timely manner.